Blood traces in negative stool tests link to bowel cancer risk
Two-year bowel cancer risk was 504.5 per 100,000 episodes for stool hemoglobin of 15 to under 20 micrograms per gram against 35.7 for 0 to 5.
Limit: The quantitative analysis included only a complete-case subset of 326,931 episodes
Edited by Boris Djordjevic · AgingResearch.News
A retrospective cohort study tracked 700,734 participants aged 50 to 74 years who had 1,083,149 negative stool screening episodes in Queensland, Australia. The researchers linked screening and cancer registry records from 2018 to 2022 to measure interval colorectal cancers, which are cancers diagnosed after a negative screening test.
Across all negative episodes, 586 cancers occurred over 2,056,405 person-years, giving a 24-month cumulative risk of 57.6 per 100,000 episodes. In a subgroup of 326,931 episodes with exact stool hemoglobin measurements, 138 cancers occurred. Stool hemoglobin concentrations greater than 15 to under 20 micrograms per gram were associated with an adjusted hazard ratio of 14.93 compared with 0 to 5 micrograms per gram. The corresponding 24-month cancer risks were 504.5 and 35.7 per 100,000 episodes. Higher negative-range concentrations were more common in males and older participants.
Why it matters
Colorectal cancer risk rises with age, making routine screening central to preventive healthcare in older adults. Tracking exact blood levels in negative tests may help clinicians tailor screening schedules for older adults at higher risk of developing tumors between rounds.
Caveats
The quantitative analysis included only a complete-case subset of 326,931 episodes, and the findings do not apply to people outside ages 50 to 74 or those diagnosed with colorectal cancer before follow-up. This study is also a preprint that has not yet been peer-reviewed.
The paper
The University of Melbourne
medRxiv, Oct 28, 2026, Open access, Preprint, not peer-reviewed
